Enhancement of chemokine function as an immunomodulatory strategy employed by human herpesviruses by Viejo-Borbolla, Abel et al.
Enhancement of Chemokine Function as an
Immunomodulatory Strategy Employed by Human
Herpesviruses
Abel Viejo-Borbolla1, Nadia Martinez-Martı´n1, Hendrik J. Nel2, Patricia Rueda3,4, Rocı´o Martı´n1, Soledad
Blanco1, Fernando Arenzana-Seisdedos3,4, Marcus Thelen5, Padraic G. Fallon2, Antonio Alcamı´1,6*
1Department of Virology and Microbiology, Centro de Biologı´a Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientı´ficas – Universidad Auto´noma de
Madrid, Madrid, Spain, 2 School of Medicine, St James’s Hospital, Trinity College Dublin, Dublin, Ireland, 3Viral Pathogenesis Laboratory, Institute Pasteur, Paris, France,
4 INSERM U819, Paris, France, 5 Institute for Research in Biomedicine, Bellinzona, Switzerland, 6Department of Medicine, University of Cambridge, Addenbrooke’s
Hospital, Cambridge, United Kingdom
Abstract
Herpes simplex virus (HSV) types 1 and 2 are highly prevalent human neurotropic pathogens that cause a variety of
diseases, including lethal encephalitis. The relationship between HSV and the host immune system is one of the main
determinants of the infection outcome. Chemokines play relevant roles in antiviral response and immunopathology, but the
modulation of chemokine function by HSV is not well understood. We have addressed the modulation of chemokine
function mediated by HSV. By using surface plasmon resonance and crosslinking assays we show that secreted glycoprotein
G (SgG) from both HSV-1 and HSV-2 binds chemokines with high affinity. Chemokine binding activity was also observed in
the supernatant of HSV-2 infected cells and in the plasma membrane of cells infected with HSV-1 wild type but not with a
gG deficient HSV-1 mutant. Cell-binding and competition experiments indicate that the interaction takes place through the
glycosaminoglycan-binding domain of the chemokine. The functional relevance of the interaction was determined both in
vitro, by performing transwell assays, time-lapse microscopy, and signal transduction experiments; and in vivo, using the air
pouch model of inflammation. Interestingly, and in contrast to what has been observed for previously described viral
chemokine binding proteins, HSV SgGs do not inhibit chemokine function. On the contrary, HSV SgGs enhance chemotaxis
both in vitro and in vivo through increasing directionality, potency and receptor signaling. This is the first report, to our
knowledge, of a viral chemokine binding protein from a human pathogen that increases chemokine function and points
towards a previously undescribed strategy of immune modulation mediated by viruses.
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Introduction
Herpes simplex virus type 1 and 2 (HSV-1 and HSV-2,
respectively) and varizella zoster virus (VZV) are the three human
members of the Alphaherpesvirinae subfamily, which establish latency
in the sensory ganglia of the peripheral nervous system. Both
HSV-1 and -2 are highly prevalent viruses with values around
90% for HSV-1 and 12–20% for HSV-2 in adult populations of
industrialized countries, reaching up to 80% for HSV-2 in
developing countries [1,2]. Infection by HSV can be either
asymptomatic, show mild symptoms in localized tissues or cause
severe diseases such as stromal keratitis or herpes simplex
encephalitis (HSE), with high mortality and neurologic morbidity
[3]. HSV infection of neonates can result in disseminated disease
including infection of the central nervous system or involve several
organs with mortality reaching 80% [4]. The causes of such
different outcomes following HSV infection or reactivation are
unknown but involve the interplay between the virus and the
immune response.
Chemokines are essential elements of the antiviral response.
They constitute a family of chemotactic cytokines that orchestrate
leukocyte migration to sites of injury or infection [5]. Chemokines
also play relevant roles in the developing and mature nervous
system [6]. The chemokine network contains more than 45
chemokines and around 20 G-protein coupled receptors (GPCR).
There are 4 subfamilies of chemokines classified on C, CC, CXC
and CX3C. All chemokines are secreted. CXCL16 and CX3CL1
are also present as membrane-anchored forms. The chemokine
network is complex, highly regulated and promiscuous, with some
receptors interacting with more than one chemokine and some
chemokines binding to more than one receptor. Alterations in the
chemokine network are responsible for inflammatory, autoim-
mune diseases and the establishment of chronic pain [7,8].
Binding of chemokine to glycosaminoglycans (GAGs) is relevant
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for chemokine function. GAGs promote chemokine oligomeriza-
tion, mediate retention of chemokines onto the cell surface
allowing chemokine recruitment in tissues, increase their local
concentration in the microenvironment surrounding the GPCR,
and modulate receptor recognition [9]. Interaction of the
chemokine with the GPCR triggers a signal cascade that includes
stimulation of mitogen activated protein kinases (MAPKs) such as
Janus-N-terminal kinase 1 and 2 (JNK1-2), extracellular signal-
regulated kinase 1-2 (ERK1/2) and p38 [10]. The proper function
of chemokines is essential to trigger an appropriate and effective
antiviral response. An exacerbated immune response, often
triggered or maintained by chemokines, may lead to immunopa-
thology. Patients suffering from HSE present higher level of
chemokine expression in the cerebrospinal fluid than healthy
individuals suggesting a relevant role for chemokines in the
pathogenesis of HSE [11].
Both pox- and herpesviruses express proteins that interfere with
chemokine function playing relevant roles in viral cycle, immune
evasion and pathogenesis [12]. One of the strategies of chemokine
interference involves the expression of secreted viral proteins that
bind chemokines and inhibit chemokine function [13]. These
proteins have been termed viral chemokine binding proteins
(vCKBP). They lack amino acid sequence similarities among
themselves or with host chemokine receptors, making difficult the
detection of such proteins by sequence analysis.
We, and others, have previously shown that secreted glycopro-
tein G (gG) from some non-human alphaherpesviruses binds to
chemokines and inhibits chemokine function. Examples of such
viruses are bovine herpesvirus 5 (BHV-5), equine herpesvirus 1
and 3 (EHV-1 and EHV-3) [14,15], pseudorabies virus (PRV) [16]
and infectious laryngotracheitis virus [17]. Chemokine-binding
activity was not observed when supernatants of cells infected with
the human viruses VZV, HSV-1 and HSV-2 were tested using
different radio-iodinated chemokines [14]. In the case of VZV, the
gene encoding for gG is not present within its genome. However,
both HSV-1 and HSV-2 contain the open reading frame us4
encoding gG. HSV-1 and HSV-2 gG (gG1 and gG2, respectively)
are present on the viral particle and on the plasma membrane of
infected cells [18–20]. gG2 is further processed and an N-terminal
fragment is secreted to the medium of the infected cells [19,20].
On the contrary, gG1 is not secreted, similarly to the rest of HSV
glycoproteins. The functions of HSV-1 and HSV-2 gGs are not
well understood. Two reports point to a role of the HSV gGs in
the initial steps of entry. HSV-1 gG seems to be important for the
infection of polarized epithelial cells [21]. The non-secreted
portion of HSV-2 gG binds heparin and the cellular plasma
membrane [22]. Deletion or disruption of us4 attenuates HSV-1 in
vivo, indicating that gG is a virulence factor, although the
mechanism(s) beneath such phenotype are unknown [23–25].
The main aim of this study was to investigate the modulation of
the immune system by HSV. We focused initially on identifying
the function of HSV gG and its possible interaction with
chemokines. We show here that secreted, soluble HSV gG (SgG)
binds both CC and CXC chemokines with high affinity through
the GAG-binding domain of the chemokine. Moreover, we could
detect chemokine-binding activity in the plasma membrane of
HSV-1 infected cells and in the supernatant of HSV-2 infected
cells. Further experiments indicate that HSV-1 full-length gG and
secreted, soluble HSV gG (SgG) are responsible for this activity. In
complete contrast to all previously described vCKBPs, HSV-1 and
HSV-2 SgGs are not inhibitors of chemokine function. Instead,
they increase chemokine-mediated cell migration both in vitro and
in vivo through a mechanism that involves GPCR signaling and
phosphorylation of MAPKs. HSV SgGs increase the potency of
the chemokine, and the directionality of cell movement. This
constitutes, to our knowledge, the first description of a chemokine
binding protein expressed by a human pathogen that potentiates
chemokine function. The data presented here suggest the existence
of a novel viral mechanism of immune modulation and provide
tools to investigate the pathways controlling chemotaxis. Given the
relevant roles played by chemokines in both the immune and
nervous systems, enhancement of chemokine function by HSV gG
may be important for HSV-mediated immunopathogenesis.
Results
Recombinant SgG from HSV-1 and HSV-2 binds CC and
CXC chemokines with high affinity
To test whether HSV gGs bind chemokines, we expressed
soluble, secreted forms of gG1 and gG2 (SgG1 and SgG2,
respectively), lacking the transmembrane and cytoplasmic do-
mains, in insect cells infected with recombinant baculovirus
vectors (Figure 1A; Protocol S1; Text S1). Following infection,
SgG1 and SgG2 were purified from the supernatant of Hi-5 insect
cell cultures by affinity chromatography and the purity of the
preparation was determined by Coomassie staining (Figure 1B).
We routinely obtained two separate bands when SgG1 was
expressed in insect cells, probably due to different levels of SgG1
glycosylation. A monoclonal antibody raised against gG1 [18]
reacted with purified SgG1 but not SgG2 (Figure 1C, middle
panel) whereas a monoclonal anti-SgG2 [26] recognized SgG2
only (Figure 1C, right panel). The anti-His antibody reacted with
both proteins (Figure 1C, left panel).
Both purified SgG1 and SgG2 were covalently coupled to
BIAcore CM5 chips and tested for chemokine binding by Surface
Plasmon Resonance (SPR). A screening with 44 commercially
available human (h) chemokines (Protocol S2) was performed
by injecting each chemokine in a BIAcore X biosensor.
Both SgG1 and SgG2 bound with high affinity hCCL18,
hCCL25, hCCL26, hCCL28, hCXCL9, hCXCL10, hCXCL11,
hCXCL12a, hCXCL12b, hCXCL13 and hCXCL14, and SgG2
also bound hCCL22 with high affinity (Figure 2A and Table 1).
As negative controls for chemokine binding we used the cysteine-
Author Summary
Chemokines are chemotactic cytokines that direct the flux
of leukocytes to the site of injury and infection, playing a
relevant role in the antiviral response. An uncontrolled,
unorganized chemokine response is beneath the onset
and maintenance of several immunopathologies. During
millions of years of evolution, viruses have developed
strategies to modulate the host immune system. One of
such strategies consists on the secretion of viral proteins
that bind to and inhibit the function of chemokines.
However, the modulation of the chemokine network
mediated by the highly prevalent human pathogen herpes
simplex virus (HSV) is unknown. We have addressed this
issue and show that HSV-1, causing cold sores and
encephalitis and HSV-2, causing urogenital tract infections,
interact with chemokines. We determined that the viral
protein responsible for such activity is glycoprotein G (gG).
gG binds chemokines with high affinity and, in contrast to
all viral chemokine binding proteins described to date that
inhibit chemokine function, we found that HSV gG
potentiates chemokine function in vitro and in vivo. The
implications of such potentiation in HSV viral cycle,
pathogenesis and chemokine function are discussed.
HSV Glycoprotein G Potentiates Chemokine Function
PLoS Pathogens | www.plospathogens.org 2 February 2012 | Volume 8 | Issue 2 | e1002497
rich domain (CRD) of ectromelia virus cytokine response
modifier B (CrmB), previously shown to lack chemokine-binding
activity [27] (not shown). The affinity constants of the interactions
between SgG1, SgG2 and the different chemokines were
calculated using the SPR technology (Table 1). Both SgG1 and
SgG2 interacted with chemokines with high affinity, in the
nanomolar range. The interaction between HSV SgGs and
chemokines was also observed by cross-linking assays (Protocol
S3; Text S1) using radio-iodinated recombinant hCCL25,
hCXCL10, and hCXCL12a (Figure 2B–D). As a negative
control we employed CrmB-CRD (Figure 2C). Competition
assays with [125I]-hCXCL12a and increasing concentrations of
cold hCXCL12a showed the specificity of SgG2-chemokine
interaction (Figure 2D).
Chemokine binding activity is present in HSV-infected
cells
We addressed whether chemokine-binding activity was present
in the HSV-1 infected cells. To this end we infected BHK-21 cells
(Protocol S4 and S5; Text S1) with HSV-1 wt and an HSV-1 virus
where expression of gG had been disrupted by the insertion of the
b-galactosidase gene [23] and determined binding of [125I]-
hCXCL10 to the cells 14 to 16 hours post infection (h.p.i.). We
could detect chemokine binding to HSV-1 wt-infected cells
(Figure 3A; Protocol S5). Binding was not observed when the
deletion mutant HSV-1DgG was used. We also obtained
supernatants from mock- or HSV-2 infected Vero cells 36 h.p.i.,
and performed a crosslinking assay with [125I]-hCXCL12a. Two
bands could be detected in the crosslinking assay (Figure 3B) that
could correspond to the high mannose 72 kDa precursor and the
34 kDa secreted protein produced during gG2 expression and
processing [19,20]. Another possibility is that the higher molecular
weight band observed corresponds to an SgG2 dimer complexed
with chemokine.
Binding of SgG to chemokines takes place mainly
through the heparin-binding domain of the chemokine
To function properly, chemokines need to interact with both
GAGs and GPCRs. We investigated the chemokine domain
involved in the interaction with HSV SgGs using two experimental
approaches.
First, to address whether HSV SgGs could affect chemokine-
receptor interaction, we performed binding assays of [125I]-
hCXCL12a and [125I]-hCCL25 with MOLT-4 cells (Protocol
S4 and S6) expressing endogenous hCXCR4 (the receptor for
hCXCL12) and hCCR9 (the receptor for hCCL25) in the
presence of SgG-containing supernatant (not shown). We also
performed binding assays of [125I]-hCXCL12a to MonoMac-1
cells expressing endogenous hCXCR4 (not shown). As a positive
control, addition of supernatant containing BHV-5 SgG inhibited
[125I]-hCXCL12a binding to MOLT-4 cells [14] (not shown).
However, similar amounts of SgG1 or SgG2 did not decrease
[125I]-hCXCL12a binding to MOLT-4 cells, MonoMac-1 cells or
[125I]-hCCL25 binding to MOLT-4 (not shown) compared to the
mock sample. Thus, SgGs do not inhibit binding of the
chemokines to their receptors.
Figure 1. Cloning, expression and purification of HSV gG. (A) Schematic representation of SgG1 and SgG2 constructs used in this study. A
fragment of the extracellular domain of both gG1 and gG2 was amplified and cloned into a baculovirus-expression vector. The putative signal
peptide from gG was substituted by the honeybee melittin signal peptide. The position of the amino acid residues is indicated. The dashed lines
indicate the fragment of the extracellular domain included in the construct. Abbreviations: SP, signal peptide; Tmb, Transmembrane domain; His,
histidine tag; HM, honeybee melittin signal peptide; ED, extracellular domain. (B) SDS-PAGE followed by coomassie staining showing purified SgG1
(left panel) and SgG2 (right panel). (C) Western blots showing the detection of SgG1 and SgG2 with an anti-histidine (left panel), an anti-gG1 (middle
panel) or an anti-gG2 (right panel) antibody. Molecular masses are shown in kilodaltons (kDa).
doi:10.1371/journal.ppat.1002497.g001
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Second, to determine the implication of the GAG-binding
domain of the chemokine in the interaction with HSV SgGs we
utilized the SPR technology. The amount of chemokine binding to
SgGs, covalently bound to a BIAcore chip, in the absence of
heparin was considered 100% of binding (Figure 4). Competition
experiments showed that increasing concentrations of heparin
impaired chemokine binding to both SgG1 and SgG2 in a
significant manner (Figure 4). As a control, each of the different
heparin concentrations used were injected independently to
confirm that no direct heparin binding to the chip occurred (not
shown).
In summary, these results indicate that SgG1 and SgG2 interact
preferentially with the GAG-binding domain of the chemokine
and do not block the binding of chemokines to cell surface specific
receptors.
Interaction of HSV SgGs with chemokines enhances
chemokine-mediated cell migration
We, and others, have previously shown that gG encoded by
several non-human alphaherpesviruses inhibits chemotaxis [14–
17,28]. To examine the functional role of the interaction between
HSV SgGs and chemokines we performed cell migration
experiments. First we addressed whether the chemokine-binding
activity observed in the supernatant of HSV-2 infected cells could
have any effect on chemotaxis. We incubated CXCL12b with
supernatant from mock- or HSV-2-infected cells and performed a
chemotactic assay with MonoMac-1 cells (monocyte-like), a cell
line that expresses hCXCR4, the receptor for hCXCL12. The
supernatant from HSV-2-infected cells significantly enhanced
chemokine function in a dose dependent manner when compared
to the supernatant from mock-infected cells (Figure 5A). To
address whether this effect could be due to SgG, we performed
chemotactic experiments using several cell lines and recombinant
protein. Incubation of SgG1 with hCXCL12b resulted in higher
MOLT-4 migration (Figure 5B). A similar result was obtained with
SgG2 whereas BHV-5 SgG inhibited hCXCL12b migration (not
shown). We then incubated SgG1 and SgG2 with hCXCL13 and
tested their effect on mouse B cells (m300-19) stably transfected
with hCXCR5, the receptor for hCXCL13 (Figure 5C, Protocol
S4). Inhibition of migration was observed with the vCKBP M3, as
expected [29,30] (Figure 5C). However, SgG1 and SgG2 required
the presence of the chemokine and were not able to induce
Figure 2. HSV-1 and HSV-2 gGs bind chemokines. (A) Sensorgrams depicting the interaction between chemokines and SgG1 (left) or SgG2
(right). The indicated chemokines were injected at a 100 nM concentration. The arrow indicates the end of injection. All curves were analyzed with
the BiaEvaluation software and represent the interaction of the chemokine after subtraction of the blank curve. Only 4 out of 11–12 positive
interactions are shown. Abbreviations: Diff. Resp., Differential response; R.U., response units; s, seconds (B, C) Crosslinking assays showing the
interaction of HSV-SgGs with [125I]-hCXCL10 (B) and [125I]-hCCL25 (C). Recombinant purified HSV-SgGs were incubated with iodinated chemokine and
crosslinked with EGS (for [125I]-hCCL25) or BS3 (for [125I]-hCXCL10). The samples were resolved by SDS-PAGE, fixed and visualized by autoradiography.
(D) Crosslinking assay between [125I]-hCXCL12a and SgG2 in the presence of increasing concentrations of cold hCXCL12a. Molecular masses are
indicated in kDa. SgG-chemokine complexes are indicated with arrows and crosslinked chemokine dimers are marked with asterisks. Abbreviations:
CRD, CrmB-cysteine rich domain.
doi:10.1371/journal.ppat.1002497.g002
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chemotaxis on their own (Figure 5C). The parental m300-19 cells,
which do not express hCXCR5, did not respond to the hCXCL13
stimulus (not shown). To test whether binding to the chemokine
was necessary for the enhancing effect, we performed chemotaxis
experiments using MonoMac-1, a cell line expressing hCXCR4
and hCCR2, the receptor for hCCL2, a chemokine not bound by
HSV SgGs (Figure 2 and Table 1). The enhancement in
chemotaxis mediated by SgGs required SgG-chemokine interac-
tion since SgG2 did not have any effect on the chemotactic
properties of hCCL2 (Figure 5D), whereas it was able to potentiate
hCXCL12b. A similar result was obtained with SgG1 (not shown).
In all cases, the enhancement in chemotaxis was dose dependent
and significant.
The effect of SgGs on chemotaxis was dependent on G protein
activation since addition of pertussis toxin (PTX) inhibited both
hCXCL12b-mediated cell migration and its enhancement medi-
ated by SgGs (Figure 5E). Finally, we examined the effect of SgG1
and SgG2 on hCXCL12b-mediated cell migration utilizing
increasing concentrations of hCXCL12b and a constant molar
ratio (1:100) between the chemokine and SgG (Figure 5F). The
effect of hCXCL12b on in vitro cell migration had the
characteristic bell-shaped curve (not shown). As a control we used
PRV-SgG, which inhibited chemokine-mediated migration [16].
However, both SgG1 and SgG2 enhanced the potency of
Table 1. Interaction affinities between SgGs from HSV-1, HSV-
2 and chemokines.
Chemokine SgG1 KD (M) SgG2 KD (M)
hCCL18 9.0261028 2.861028
hCCL22 n.b. 5.2261029
hCCL25 4.761029 1.661029
hCCL26 5.561028 1.7261029
hCCL28 6.861028 3.261029
hCXCL9 3.861028 1.2361028
hCXCL10 4.5761027 5.561029
hCXCL11 1.0961028 661029
hCXCL12a 3.1561028 6.561029
hCXCL12b 7.761029 2.261029
hCXCL13 1.361028 4.361029
hCXCL14 4.261027 4.361029
The derived kinetic parameters and the affinity constants for the interactions
between HSV SgGs and chemokines are shown. Abbreviations: n.b., not bound.
doi:10.1371/journal.ppat.1002497.t001
Figure 3. HSV-1 and HSV-2 gG expressed during infection bind chemokines. (A) Graph showing binding of radio-iodinated hCXCL10 to the
surface of HSV-1 infected cells. Binding is observed at 14–16 h.p.i., only when cells are infected with wt HSV-1 but not when infected with a HSV-
1DgG mutant. (B) Crosslinking assay showing the interaction between [125I]-hCXCL12a and HSV-2 gG in the supernatant of HSV-2 infected cells. The
arrows point to the crosslinked complex. Abbreviations: h.p.i, hours post-infection. **P,0.01.
doi:10.1371/journal.ppat.1002497.g003
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hCXCL12, displacing the chemotactic bell-shaped curve towards
lower concentrations of the chemokine.
HSV SgG enhances chemokine efficiency and
directionality
To analyze the impact of HSV SgG on different aspects of
chemotaxis in real time we performed time-lapse video microscopy
using freshly isolated human monocytes and hCXCL12b. The
chemokine, alone or in combination with SgG2, was released from
a micropipette with constant backpressure. Analysis of tracks
recorded by time-lapse video microscopy from cell cultures
stimulated with CXCL12b (Video S1) or CXCL12b-SgG2 (Video
S2) clearly showed that chemotaxis in the presence of the viral
protein was enhanced, compared to the migration towards the
chemokine alone (Videos S1, S2 and Figure 6B). SgG2 was not
able to trigger migration in the absence of the chemokine (Video
S3). Consistent with our data from transwell assays (Figure 5),
SgG2 greatly enhanced the number of human monocytes that
moved towards a given concentration of the chemoattractant
(Figure 6). The cells sensed the chemokine gradient from longer
distance to the dispensing pipette than when chemokine was
dispensed alone. Chemotactic parameters, i.e. velocity, FMI and
distance traveled, were calculated during an initial 10-min period.
The velocity of the cell movement and the Forward Migration
Index (FMI), i.e. the ratio of the net distance the cell progressed in
the forward direction to the total distance the cell traveled, were
significantly increased when SgG2 was bound to CXCL12b
(Figure 6C, D). Moreover, the cells travelled a longer distance
when the chemokine and SgG2 were dispensed together than
when the chemokine was dispensed alone (Figure 6E). Similar
results were obtained when using CXCL12a (not shown).
Transwell experiments performed in parallel with freshly isolated
human monocytes confirmed the SgG2-mediated enhancement of
CXCL12b chemotaxis observed by video microscopy (Figure 6F).
Interaction of HSV SgGs with chemokine increases
chemokine-mediated signaling
MAPKs are involved in several cellular processes including cell
migration [31]. Binding of chemokine to its receptor activates a
signaling cascade that involves phosphorylation and, thereby,
activation of MAPKs. Incubation of MonoMac-1 cells with low
doses of hCXCL12b resulted in low activation of MAPKs
(Figure 7). Pre-incubation of different concentrations of
hCXCL12b with a constant molar ratio (1:200) of SgG1 enhanced
the phosphorylation of ERK (Figure 7A and B). The SgG1-
mediated increase in the phosphorylation of JNK1-2 was dose-
dependent (Figure 7C and D). Similar results were obtained with
SgG2 (not shown). Densitometer analysis of the blots shows a dose-
dependent enhancement of MAPK activation in the range of 5
fold for both ERK and JNK at the highest chemokine
concentration. These results showed, using a different biological
assay, a similar enhancement of chemokine activity mediated by
HSV SgGs. Activation of CXCR4 results in the dissociation of
GDP from the Gabc heterotrimer followed by association of GTP
to the Ga subunit. In order to measure the effect of HSV SgG on
receptor occupancy we performed a [35S]-GTPcS binding assay.
The results show that the incubation of CXCL12b with SgG
results in higher levels of [35S]-GTPcS incorporation (Figure 7E).
HSV-2 SgG increases chemotaxis in vivo
We tested the functional relevance of SgG2-chemokine
interaction in vivo using the mouse air pouch model, by performing
injections of chemokine alone or in combination with SgG2.
Injection of 0.2 mg of mCXCL12a or mCCL28 induced the
migration of leukocytes into the air cavity (Figure 8). The presence
of 2 mg SgG2 enhanced CXCL12a-mediated migration
(Figure 8A) of total leukocytes (top panel, P,0.001), lymphocytes
(middle panel, P,0.001) and granulocytes (bottom panel,
P,0.05). As a control, we used 2 mg recombinant secreted gG
from PRV (PRV-SgG), a vCKBP shown to inhibit chemotaxis
[16]. PRV-SgG significantly inhibited CXCL12a-mediated che-
motaxis of total leukocytes (top panel, P,0.001) and granulocytes
(bottom panel, P,0.05). CCL28-mediated chemotaxis (Figure 8B)
of total leukocytes (top panel) and lymphocytes (middle panel) was
significantly increased by SgG2 (P,0.05), whereas the migration
of granulocytes (bottom panel) was not affected by SgG2. This
could be explained by the specificity of CCL28 in driving T cell
chemotaxis. In contrast to the inhibition observed when CXCL12
was used, PRV-SgG did not significantly inhibit CCL28-mediated
chemotaxis. This may be due to uncontrolled factors such as the
stability of the PRV-SgG-CCL28 complex in vivo or the indirect
Figure 4. Determination of the chemokine domain involved in the interaction with HSV gGs. Heparin competition of chemokine binding
to SgG1 and SgG2. hCXCL12a was injected at a concentration of 100 nM alone or in combination with the indicated increasing concentrations of
heparin. The value of chemokine binding without heparin was considered 100%. All curves were analyzed with the BiaEvaluation software and
represent the interaction of the chemokine after subtraction of the HBS-EP curve. The error bars represent the standard error of three independent
experiments. *P,0.05; P,0.001.
doi:10.1371/journal.ppat.1002497.g004
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Figure 5. HSV SgGs enhance chemokine-mediated cell migration. MonoMac-1 cells (A, D, E, F), MOLT-4 (B), m300-19-hCXCR5 (C) cells were
incubated with the specified chemokine in Transwell plates. The effect of mock- or HSV-2-infected supernatant (Mock SN or HSV-2 SN, respectively)
(A), purified SgG1 (B, C, E, F), SgG2 (C–F), M3 (C) and PRV-SgG (F) was analyzed. The number of migrated cells or the fold activation of migration is
depicted. (C) SgG1 or SgG2 require the presence of the chemokine to enhance migration since addition of either of them without chemokine did not
have any effect on chemotaxis. (D) Binding of HSV SgGs to the chemokine is necessary for the enhancement in chemotaxis. Representation of the
HSV Glycoprotein G Potentiates Chemokine Function
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activation of other chemoattractants that may also induce
migration. Injection of SgG2 or PRV-SgG alone, in the absence
of chemokine, did not result in differences in leukocyte chemotaxis
when compared to PBS injection.
Discussion
HSV glycoproteins play relevant roles in the viral cycle and
pathogenesis, and constitute promising vaccine candidates
[32,33]. Among all HSV glycoproteins, gG is the least well
characterized and its function has not been fully elucidated. A
role for HSV gG on virus entry has been suggested. HSV-1 gG
seems to be important for the infection of, but not initial binding
to, polarized cells through the apical surface [21]. The non-
secreted domain of HSV-2 gG could participate in initial
interaction of the virion with the cell surface [21,22]. A synthetic
peptide encompassing amino acids 190–205 from the secreted
domain of HSV-2 gG was found to have a proinflammatory role
in vitro when bound to the formyl peptide receptor [34]. However,
until present, no function has been attributed to the full-length
secreted portion of HSV-2 gG. Here, we have investigated the
function of secreted forms of gG from HSV-1 and HSV-2. We
show for the first time a chemokine-binding activity both in HSV-
1 infected cells and in the supernatant of HSV-2 infected cells.
Disruption of the HSV-1 gG expression abrogated chemokine
binding suggesting that HSV gG is the protein responsible for the
interaction. We could indeed show that both HSV-1 and HSV-2
SgG bind with high affinity, in the nanomolar range, CC and
CXC chemokines. This interaction was demonstrated by the use
of two different experimental approaches: crosslinking assays and
SPR. Finally, and more importantly, we describe the first
vCKBP, to our knowledge, with the ability to increase chemotaxis
both in vitro and in vivo by enhancing the potency of the
chemokine and the directionality of cell migration. HSV SgGs
enhancement of chemotaxis required the interaction with the
chemokine through the chemokine GAG-binding domain and
involved signaling through the GPCR and activation of MAPKs.
We confirmed that supernatant containing gG secreted following
fold activation of migration observed when cells were incubated with either hCXCL12b or hCCL2 in the absence or presence of increasing
concentrations of HSV-2 gGs. (E) Addition of pertussis toxin (PTX) inhibits SgG-mediated enhancement of chemotaxis. Graph showing the effect of
PTX addition on HSV SgGs enhancement of hCXCL12b-mediated chemotaxis. The number of migrated MonoMac-1 cells is represented. (F) HSV SgGs
displace the hCXCL12b chemotactic curve towards lower concentrations of chemokine. MonoMac-1 cells were incubated with increasing
concentrations of hCXCL12b in the absence or presence of a 1:100 molar ratio of HSV SgGs or PRV-SgG. (A–F) Error bars indicate standard deviation
values obtained from triplicate samples (A, C, E, F). One representative experiment of at least three is shown. In B and D, error bars represent the
standard deviation in the fold activation obtained using three independent experiments performed in duplicate. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.ppat.1002497.g005
Figure 6. Analysis of SgG2 induced enhancement of chemotaxis by time-lapse video microscopy. (A) Selected frames from Videos S1
and S2 showing migration towards CXCL12 (left) or CXCL12-SgG2 (right). (B) Migrating cells were tracked and their progressive trajectories were
plotted according to the recorded xy coordinates. Orange dots indicate the real position of the micropipette dispensing CXCL12 (left) or CXCL12-
SgG2 (right). Each line represents the path followed by one cell during 10 min at the initial phase of chemotaxis. (C) The velocity of cell movement,
(D) forward migration index and (E) total traveled distance by cells migrating towards the micropipette dispensing CXCL12 or CXCL12-SgG2 were
plotted. Representative data from 6 cells (CXCL12) and 10 cells (CXCL12-SgG2) migrating at the initial time period are shown. Time-lapse videos were
analyzed using Image J 1.43 software. The trajectories of the tracks, velocities, FMI and distances traveled were calculated using Manual Tracking and
Chemotaxis Tool version 1.01 plugging. The analysis of 1 representative video out of three is shown. (F) Representation of migrated monocytes in the
presence of CXCL12 alone or in combination with SgG2 using the transwell technology. 1 representative experiment out of three is shown. Error bars
indicate standard error values. *:P,0.05; **:P,0.01; ***:P,0.001.
doi:10.1371/journal.ppat.1002497.g006
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HSV-2 infection enhances chemokine-mediated migration of
leukocytes. Moreover, in preliminary experiments we have found
that membrane-anchored gG expressed during HSV-1 replica-
tion in cell culture also enhances chemokine activity (N.M.-M.
and A.V.-B., unpublished data).
During evolution, viruses have developed strategies to modulate
the host immune response. Inhibition of chemokine function
through the expression of vCKBP is a common strategy in
members of the Poxviridae family [12,35] indicating the importance
of chemokines in antiviral defense. In the Herpesviridae family,
Figure 7. HSV SgG enhances chemokine-mediated signaling. (A) Western blots showing activation of ERK (p-ERK, top blot) and loading
control (Total ERK, bottom blot) in MonoMac-1 cells incubated with CXCL12 alone or with a constant 1:200 molar ratio of chemokine:SgG1. (C)
Western blot showing the effect of increasing concentrations of HSV SgG1 on chemokine-mediated JNK phosphorylation (top blot). As loading
control, the blots were stripped and incubated with anti-alpha-tubulin (bottom blot). (B and D) Graphs depicting the results obtained after
performing a densitometer analysis of the blots. The densities obtained from each of the lanes in the MAPKs blots were normalized to the loading
controls and later to the mock sample. (E) Graph showing the percentage of [35S]-GTPc binding to CXCR4 mediated by CXCL12 alone or with SgG2
(considering no CXCL12 as 100%). The results of combining three independent experiments performed in duplicate are shown. Error bars indicate
standard deviation values. * P,0.05.
doi:10.1371/journal.ppat.1002497.g007
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however, there are only three examples of vCKBP reported to
date, two of them expressed by animal viruses -gG from
alphaherpesviruses and M3 from murine herpesvirus 68- and
one expressed by a human pathogen, pUL21.5 encoded by human
cytomegalovirus [14,36]. In addition, interaction of HSV gB with
a reduced number of chemokines has been reported [37].
However, this interaction was of low affinity, in the micromolar
range [37] compared to the nanomolar range observed for all
vCKBP [14,16,17,29,30,36]. Moreover, gB did not seem to have
an effect on chemotaxis [37]. Nearly all previously described
vCKBP have been shown to inhibit chemotaxis either in vitro or in
vivo. As a general rule, vCKBPs inhibit chemokine function
through impairing chemokine-receptor interaction or chemokine
presentation by GAGs [38]. For instance, gG from some animal
alphaherpesviruses blocks chemokine interaction with its receptor
[14,28] and with GAGs [14] inhibiting chemotaxis [14,16,17]. To
date, there are no reports of a vCKBP that potentiates chemokine
function either in vitro or in vivo. HSV SgG is, therefore, the first
vCKBP described, to our knowledge, which enhances chemokine
function both in vitro and in vivo.
Our studies with SgG1 and SgG2 show that these viral proteins
interact with the GAG-binding domain of the chemokines and
enhance the chemokine activation of GPCRs. Chemokine-GAG
interaction is required for correct chemokine function in vivo [9].
Several reports show that GAG-binding deficient chemokines are
functionally impaired in vivo and when in vitro migration and
invasion assays are performed [39,40]. GAGs also modify
chemokine quaternary structure and this seems to be required
Figure 8. HSV-2 SgG enhances chemokine-mediated cell migration in vivo. CXCL12a (A) or CCL28 (B) were injected into dorsal air pouches
in mice alone or in combination with HSV-2 SgG or PRV SgG. Cell migration into the air cavity was monitored. Cells were extracted and identified by
flow cytometry with specific markers. The number of total leukocytes (top), lymphocytes (middle) and granulocyte cells (bottom graph) is
represented. Data are mean and SEM from 5–6 mice per group and are representative of 2–3 separate experiments. *:P,0.05; **:P,0.001.
doi:10.1371/journal.ppat.1002497.g008
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for chemokine function [39,41]. We propose a model in which
SgG1 and SgG2 act similarly to the GAGs, maybe by increasing
the local chemokine concentration, modifying the chemokine
quaternary structure or improving chemokine presentation to the
receptor so that signaling is enhanced. This would cause the
observed activation of chemokine signaling at lower doses of
chemokine when gG is present. This contrasts with the related gGs
encoded by non-human herpesviruses, which have been shown to
inhibit chemokine-mediated signal transduction and cell migration
[14–17]. It appears that HSV-1 and HSV-2 have evolved a
vCKBP to enhance, rather than to inhibit, chemokine function,
and this may represent an advantage to these human herpesvi-
ruses.
The functional relevance of chemokine enhancement in HSV
life cycle and pathogenesis is unknown. The role of alphaherpes-
virus gG in vivo is not fully understood. Results presented in several
reports indicate that gG from animal alphaherpesviruses is
relevant for pathogenesis and immune modulation [15,17]. There
are currently no data on the role of HSV-2 gG on pathogenesis.
Three independent reports show that lack of gG expression in
HSV-1 leads to different degrees of virus attenuation [23–25].
Thus, lower viral titers were detected in mouse tissues infected
through scarification of the ear with an HSV-1 mutant lacking gG
[23]. A double us3/us4 deletion mutant (with us3 encoding a kinase
and us4 encoding gG) was attenuated following intracranial
injection [24]. However, the relative contribution of either protein
in that animal model could not be defined. Mutation of the us4
gene by the use of transposon Tn5 resulted in a HSV-1 mutant
that was less pathogenic, was deficient in its ability to replicate in
the mouse central nervous system and caused a delay in
encephalitis induction [25]. The mechanisms of attenuation of
HSV-1 gG mutant viruses are unknown, but the discovery that
HSV-1 gG enhances chemokine function points to a role of HSV
gG on deregulation of chemokine function that could explain the
lower pathogenicity observed with the mutant viruses.
Although there are not yet systematic analyses on the expression
of all known chemokines on the tissues relevant for HSV infection,
the information obtained by several laboratories supports the
relevance of chemokines on HSV infection and pathogenesis. The
expression of some chemokines is upregulated upon HSV-1 and
HSV-2 infection [42,43] leading to leukocyte infiltration, which
may be as pathogenic as viral infection [44]. In fact, chemokines
are important in HSE pathogenesis in humans [11]. Deficiency in
CXCR3 or CCR5 increases susceptibility to genital HSV-2
infection although through different mechanisms [43,45]. Inter-
estingly, the lack of CXCR3 does not result in lower leukocyte
recruitment. On the contrary, CXCR32/2 mice show an increase
in viral titers, infiltrating cells and neuropathology accompanied
by a higher level of cytokine and chemokine expression in brain
and spinal cord [46]. Differences were observed between
CXCL102/2 and CXCR32/2 (the receptor for CXCL10) mice
when challenged with ocular HSV-1 infection [47,48]. However,
CXCR32/2 responded like CXCL92/2 or CXCL102/2 in a
genital model of HSV-2 infection [46]. There are also differences
in susceptibility depending on the route of infection and the nature
of the pathogen employed. The redundancy of the chemokine
network may be beneath some of these differences and
discrepancies.
The chemokines bound by SgG1 and SgG2 are expressed in
tissues relevant for HSV infection, replication and spread. Among
other cell types, mucosal epithelial cells express CCL25, CCL28
and CXCL13: (1) CCL25 expression is upregulated during oral
wound healing [49]; (2) CCL28 is expressed in airway epithelial
cells [50]; and (3) CXCL13 is required for the organization and
function of the nasal-associated lymphoid tissue [51]. Human
corneal keratinocytes express CXCL9, CXCL10 and CXCL11,
expression that can be further induced by proinflammatory
cytokines [52]. CXCL14 expression in taste-bud cells is remark-
ably high and secreted to the saliva [53]. Among other tissues,
CXCL12 is expressed in nervous tissues where it has been
suggested to play a role in leukocyte extravasation [54]. CXCL12
also induces migration of neural progenitors, is required for axonal
elongation and pathfinding, is relevant for neurotoxicity and
neurotransmission in the adult nervous system and contributes to
chronic pain [6,8]. Thus, modulation of the activity of chemokines
mediated by gG1 and gG2 could occur in tissues infected by HSV
and play a role in HSV biology.
Enhancement of chemokine function by HSV SgGs could
impact at least four different scenarios relevant for HSV spread
and pathogenesis. First, enhancement of GPCR signaling could
aid in the early steps of infection and in viral replication. In fact,
MAPK activation is required for efficient HSV replication [55]. In
this scenario gG1, due to its presence in the viral particle and at
the plasma membrane of the infected cells, may play a more
relevant role than gG2, which is processed secreting its chemokine-
binding domain. Second, increase in the level of infiltrating
leukocytes, or differences in the composition of such infiltrate,
could skew the immune response and favor viral replication. The
fact that HSV SgGs only bind 11–12 out of 45 human chemokines
with high affinity suggests the existence of a selectivity and
specificity in the modulation of the immune response. Third,
enhancement in the migration of a particular leukocyte population
could recruit cells that may be subsequently infected by HSV,
enhancing viral load. Fourth, modulation of chemokines present in
the nervous system, such as CXCL12, could play a role in the
initial infection of the ganglia, sites of HSV latency, and increase
the ability of HSV to persist and cause disease. The impact of
HSV gG-chemokine interaction on HSV biology requires further
characterization.
In summary, this is the first report of a vCKBP that enhances
chemokine function and suggests a novel mechanism of immune
modulation mediated by a highly relevant and prevalent human
pathogen. The findings reported here shall foster further
investigations on the role of HSV gG on pathogenesis and
immune modulation and will allow the design of novel
immunomodulators, antiviral drugs and tools to study chemokine
function.
Materials and Methods
Ethics statement
All animal experiments were performed in compliance with
Irish Department of Health and Children regulations and
approved by the Trinity College Dublin’s BioResources ethical
review board. Human peripheral blood monocytes were prepared
from buffy coats obtained from the local donor bank (‘‘Servizio
Trasfusione, Svizzera Italiana’’, CH-6900 Lugano, Switzerland),
with oral consent from the donors according to Swiss regulations.
The use of buffy coats was approved by the institutional review
board ‘‘Comitato Etico Cantonale, CH-6501 Bellinzona, Switzer-
land’’ and the experimental studies were approved by the
‘‘Dipartimento della Sanita´ e della Socialita´’’.
Determination of SgG-chemokine binding specificity and
affinities using SPR technology
The interactions between chemokines and SgGs and their
affinity constants were determined by SPR technology using a
Biacore X biosensor (GE Healthcare) as previously described [16].
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Both proteins were dialyzed against acetate buffer (pH 5.0 for
SgG1 and pH 5.5 for SgG2) prior to amine-coupling of the
recombinant proteins in CM5 chips. Chemokines that did not
bind under kinetic conditions were considered negative and not
taken into further consideration for the study. In competition
experiments with heparin the chemokine was injected at 100 nM
alone or with increasing concentrations of heparin in HBS-EP
buffer (10 mM Hepes, 150 mM, NaCl, 3 mM EDTA, 0.005%
(vol/vol) surfactant P20, pH 7.4) at a flow rate of 10 ml/min, and
association and dissociation were monitored. All Biacore sensor-
grams were analyzed with the software Biaevaluation 3.2. Bulk
refractive index changes were removed by subtracting the
reference flow cell responses, and the average response of a blank
injection was subtracted from all analyte sensorgrams to remove
systematic artifacts.
Competition of chemokine binding to cells
Competition experiments were carried out incubating 0.5 pmol
of [125I]-hCCL25 or [125I]-hCXCL12a with or without different
concentrations of SgGs (or baculovirus supernatants) at 4uC in
binding medium (RPMI 1640 containing 1%FBS and 20 mM
HEPES pH 7.4) during 1 h at 4uC. Then, 36106 MOLT-4 or
MonoMac cells were added to the mixture and incubated for
further 2 h at 4uC with gentle agitation, subjected to phthalate oil
centrifugation, washed twice with PBS, and cell-bound chemokine
was determined using a gamma-counter.
Chemotaxis assays
Chemokines were placed in the lower compartment of 24-well
transwell plates (Costar) or in 96-well ChemoTx System plates
(Neuro Probe Inc., MD, USA) with or without recombinant gGs in
RPMI 1640 containing 1% FBS. MOLT-4, MonoMac-1, m300-
19 and m300-19-hCXCR5 cells were placed on the upper
compartment (36105 cells in the 24-well transwell plate and
1.256105 cells in the 96-well ChemoTx System plate, with the
exception of m300-19-hCXCR5 where 2.56105 cells were used).
To test the effect of supernatant from mock- or HSV-2-infected
cells in chemotaxis, the cells were infected in the presence of
Optimem (Gibco) and the supernatants were collected 36 h.p.i.
These supernatants were inactivated with psoralen as previously
described [56] and concentrated 10 times using a Vivaspin 500
(Sartorius) prior to use. Both chambers were separated by a 3 mm
(for MOLT-4, MonoMac-1 cells and monocytes) or 5 mm (for
m300-19 and m300-19-hCXCR5 cells) pore size filter. The plates
were incubated at 37uC during 2–4 h and the number of cells in
the lower chamber was determined using a flowcytometer (for 24-
well transwell plates) or by staining the cells with 5 ml of CellTiter
96 aqueous one solution cell proliferation assay (Promega, WI,
USA) during 2 h at 37uC and measuring absorbance at 492 nm,
with the exception of monocytes and m300-19-hCXCR5 which
were counted with a light microscopy. When the CellTiter 96
aqueous one solution cell proliferation assay was used, known
amounts of cells were incubated with the CellTiter solution to
quantify the number of migrated cells. When used, PTX was
incubated with MonoMac-1 cells overnight at a concentration of
0.1 mg/ml, prior to the chemotaxis experiment.
Isolation of human monocytes from blood and time-
lapse video microscopy
Monocytes were isolated from blood of healthy donors by
negative selection using Monocyte Isolation kit II (MACS Miltenyi
Biotec). Peripheral blood mononuclear cells (PBMBs) were isolated
from heparinized blood by Ficoll (Lymphoprep) gradient centri-
fugation. Cells were resuspended in MACs buffer and incubated
with FcR blocking reagent at 4uC. Monocytes were purified by
negative selection according to the manufacturer’s protocol. Time-
lapse video microscopy analysis of chemotaxis was performed
immediately with a Leica DI6000 microscope stand connected to a
SP5 scan head equipped with a temperature controlled chamber
(Cube, LIS, Basel). Freshly isolated monocytes were placed in a
humidified and CO2-controlled incubator, which was mounted on
the microscope stage (Brick, LIS, Basel). Cells were resuspended in
D-PBS containing calcium and magnesium (Invitrogen) supple-
mented with 1% FBS, Pen/Strep, 0.04 mM sodium pyruvate,
1 mg/ml fatty acid free BSA (Sigma), 1 mg/ml glucose (Fluka).
Cells were plated on glass bottom petri-dishes (MatTek culture-
ware) which were coated previously with D-poly-lysine (5 mg/ml)
and subsequently overlaid with 3 mg/ml VCAM-1 (BD Bioscienc-
es) at 4uC overnight. Before plating the cells, coated-dishes were
treated with PBS containing FBS and BSA to block non-specific
binding. Chemokine was dispensed with a micropipette (Femtotip
II, Eppendorf) controlled by a micromanipulator (Eppendorf) at a
constant backpressure of 30 hPa (Femtojet, Eppendorf).
Activation of mitogen activated protein kinases
Chemokine alone or in combination with SgGs was added to
106 MonoMac-1 cells and incubated during 1 min at 37uC. Cells
were lysed in lysis buffer (20 mM triethanolamine pH 8.0,
300 mM NaCl, 2 mM EDTA, 20% glycerol, 1% digitonin and
proteinase inhibitors). The lysate was analyzed by western blotting
using anti-phospho-ERK, anti-phospho-P38 (Cell Signaling Tech-
nology) or anti-phospho-JNK1/2 polyclonal antibodies (Abcam).
Blots were scanned and the densities of the bands were analyzed
and compared with the Image J 1.43 software normalizing the
densities obtained from each band from the MAPK blots to their
respective loading controls.
Air pouch model
Age-matched female C57BL/6 mice from Harlan (Bicester,
U.K.) were housed in a specific pathogen-free facility in
individually ventilated and filtered cages under positive pressure.
All animal experiments were performed in compliance with Irish
Department of Health and Children regulations and approved by
the Trinity College Dublin’s BioResources ethical review board.
Dorsal air pouches were induced in mice as described [57]. In
brief, 5 ml of sterile-filtered air was injected subcutaneously into
the dorsal skin of mice, with air pouches re-inflated with 3 ml of
sterile air 3 days later. The dorsal air pouches of groups of 5–6
mice were injected 2 days later with 0.2 mg chemokine alone or in
combination with 2 mg SgG. Mice were killed and air pouches
were lavaged with PBS 3 h later. The air pouch aspirate was
centrifuged and total leukocytes cells were counted.
Cells were stained with a panel of mAbs for surface markers for
flow cytometric cell characterization as described [58]. mAbs used
were from BD Biosciences; PerCP anti-CD4 (RM4-5), PerCP-
Cy5.5 anti-CD19 (1D3), PerCP anti-CD8a (53-6.7), PerCP anti-
CD11b (M1/70) and eBioscience: PE anti-Ly6G (RB6/8C5). Cells
were defined as lymphocytes (CD4+CD8+CD19+) and Ly6-
GhiCD11b+ granulocytes (neutrophils). Data were collected on a
CyAn (Beckman Coulter) and analyzed using FlowJo (Tree Star).
Quadrants were drawn using appropriate isotype-controls and
data plotted on logarithmic scale density- or dot-plots.
Statistical analysis
Statistical analyses of data were performed with the program
GraphPad Prism. The significant value (P value) for the
parameters measured in all assays was calculated using the
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student’s t-test with the exception of the ones obtained in the air-
pouch model experiments which was calculated using the one-way
analysis of variance (ANOVA).
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donors were plated on glass bottom cover slips coated with Poly-D-
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micropipette with constant backpressure. Time-lapse video was
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Video S2 Migration of human monocytes towards
CXCL12b-SgG2. Freshly isolated monocytes from blood of
healthy donors were plated on glass bottom cover slips coated with
Poly-D-lysine and VCAM-1. CXCL12b (100 nM) was pre-
incubated with SgG2 in a molar ratio 1:50 during 30 min at
RT. CXCL12 and SgG2 complex was dispensed from a
micropipette with constant backpressure. Time-lapse video was
recorded at 10 seconds interval with DIC optics at 636
magnification. 1 representative video of three is shown. DiVX
software should be used to open and play this video.
(AVI)
Video S3 Migration of humanmonocytes towards SgG2.
Freshly isolated monocytes from blood of healthy donors were
plated on glass bottom cover slips coated with Poly-D-lysine and
VCAM-1. 5 mM SgG2 was dispensed from a micropipette with
constant backpressure. Time-lapse video was recorded at 10 sec-
onds interval with DIC optics at 636magnification.
(MOV)
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